Mereo BioPharma Group plc
MREO
$0.32
$0.013.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 24.33% | 3.18% | 8.26% | -34.47% | -79.15% |
| Total Depreciation and Amortization | 9.33% | 5.61% | -24.11% | 2.65% | -2.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.21% | 33.62% | -53.12% | 104.35% | 39.47% |
| Change in Net Operating Assets | -184.75% | -768.02% | 97.00% | -126.06% | 117.95% |
| Cash from Operations | 18.74% | 5.67% | -8.30% | -64.39% | -66.90% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 100.00% | 100.00% | 57.08% | 57.29% |
| Cash from Investing | 100.00% | 97.14% | 97.14% | 54.22% | 54.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.92% | -98.88% | -98.96% | -99.17% | 309.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 85.40% | 76.67% | 70.60% | -14.11% | -106.76% |
| Cash from Financing | -100.20% | -99.29% | -99.46% | -100.63% | 484.08% |
| Foreign Exchange rate Adjustments | 5.91% | 895.71% | -75.75% | 353.98% | -48.80% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -289.97% | -332.70% | -276.87% | -190.84% | 224.00% |